Germoloids Cream
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Germoloids Cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Zinc oxide Ph. Eur. 6.6% w/w
Lidocaine hydrochloride Ph. Eur. 0.7% w/w
3 PHARMACEUTICAL FORM
Cream for topical and rectal administration.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
The symptomatic relief of pain, swelling, irritation and itching associated with haemorrhoids and pruritus ani.
4.2 Posology and method of administration
Adults and children aged 12 years and over:
Apply at least twice a day with a minimum of three to four hours between applications. Further applications can be made at any time of day and are particularly recommended after bowel movement.
Do not use more than four times in any 24 hour period.
External piles and pruritus ani:
Apply to the affected area.
Internal piles:
Gently insert applicator into the anal opening and expel a small amount of the cream by squeezing the tube gently.
Children under 12 years:
Only as directed by a doctor.
The elderly:
Use as per adult directions.
4.3 Contraindications
Hypersensitivity to any of the constituents.
4.4 Special warnings and precautions for use
Persons who continually suffer from haemorrhoids or who have severe haemorrhoids or who experience excessive bleeding, are advised to consult a doctor.
4.5 Interaction with other medicinal products and other forms of interaction
None known for topical preparations
4.6 Pregnancy and lactation
There is a lack of definitive evidence of safety of the product in human pregnancy and lactation. However, lidocaine hydrochloride and zinc oxide have been in wide use for many years without apparent ill consequence. It is not necessary to contraindicate this product in pregnancy and lactation provided caution is exercised and the directions for use are followed. However, as with all medicines, the advice of a doctor should be sought.
4.7 Effects on ability to drive and use machines
None
4.8 Undesirable effects
Very rarely increased irritation may occur at the site of application.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
It is very unlikely that overdosage would occur from this pharmaceutical form. Symptoms of lidocaine overdosage would be unlikely to occur even after anal insertion of 25g of cream.
Normally there should be no systemic adverse effects, but at worst CNS and cardiovascular effects are possible. Treatment would be symptomatic after withdrawal of product.
In the case of accidental oral ingestion, the advice of a doctor should be sought.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Zinc oxide has astringent, antiseptic, soothing and protective properties. Lidocaine hydrochloride has a local anaesthetic action.
The cream base has emollient properties.
5.2 Pharmacokinetic properties
The product has a local action with minimal risk of systemic effects. Lidocaine has a fast onset and intermediate duration of action. It is partially absorbed but plasma levels will be low in view of the concentration of lidocaine in the product. It undergoes de-ethylation in the liver where clearance approaches the rate of hepatic flow.
5.3 Preclinical safety data
Preclinical safety data on these active ingredients in the literature, have not revealed any pertinent and conclusive findings which are of relevance to the recommended dosage and use of the product.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Polawax
White soft paraffin Methyl salicylate Methyl hydroxybenzoate Butyl hydroxybenzoate Purified water.
6.2 Incompatibilities
None known
6.3 Shelf life
Three years
6.4 Special precautions for storage
Store below 25oC.
6.5 Nature and contents of container
a) Flexible aluminium tubes internally lacquered, fitted with a polypropylene screw cap. 25, 27.5 or 55g tubes are contained in boxboard cartons, together with a polyethylene screw-on applicator nozzle.
b) Aluminium laminate tube consisting of 150pm Polyethylene /5pm polyacrylate outer layer, 30pm aluminium and an inner layer of 30pm polyacrylate / 60pm polyethylene, fitted with a HD polyethylene shoulder, an aluminium/surlyn tamper evident seal, polypropylene cap and a loose polyethylene screw-on applicator nozzle.
6.6 Special precautions for disposal
Not applicable.
7 MARKETING AUTHORISATION HOLDER
Bayer plc
Trading style: Bayer plc; Consumer Care Division
Bayer House
Strawberry Hill
Newbury
Berkshire
RG14 1JA
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 00010/0265
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
26/11/1990 / 19/03/2001
10 DATE OF REVISION OF THE TEXT
13/11/2015